CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 304 enrolled
Drug / intervention
LY2623091 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02194465
NCT02194465Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension

Eli Lilly and Company·interventional·Posted Jul 18, 2014·Updated Jun 26, 2020

In Brief

A Phase 2 clinical trial evaluating LY2623091, Tadalafil, and 2 other interventions for Primary Hypertension. Completed, enrolled 304 participants across 43 sites in 3 countries.

Detailed Summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hypertension
CountriesCanada, Puerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 18, 2014
Enrollment StartAug 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.0 years ago

Interventions

LY2623091drug

Administered orally

Tadalafildrug

Administered orally

Spironolactonedrug

Administered orally

Placebodrug

Administered orally